AQR Capital Management
BNGO icon

AQR Capital Management’s Bionano Genomics BNGO Stock Holding History

AQR Capital Management’s Portfolio BNGO Stock Details BNGO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-196
Closed -$352K – 2221
2021
Q4 		$352K Buy
196
+32
+20% +$85.6K ﹤0.01% 1935
2021
Q3 		$541K Buy
164
+102
+165% +$357K ﹤0.01% 1836
2021
Q2 		$273K Buy
+62
New +$245K ﹤0.01% 2063

Other funds holding BNGO

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Bank Julius Baer & Co
Bank Julius Baer & Co Zurich, Switzerland $33.2B AUM 25.01% 1-Year Est. Return
Allianz Asset Management
Allianz Asset Management Munich, Germany $95.4B AUM 38.74% 1-Year Est. Return
Mitsubishi UFJ Asset Management
Mitsubishi UFJ Asset Management Tokyo, Japan $149B AUM 24.71% 1-Year Est. Return

AQR Capital Management's BNGO Position: Q1 2022 in Review

AQR Capital Management sold out of Bionano Genomics (BNGO) in Q1 2022, closing a stake of 196 shares — an estimated $352K sold.

AQR Capital Management first reported a position in BNGO in Q2 2021 and held it in 3 quarters. The position peaked at $541K in Q3 2021. 148 funds tracked by Wall St. Rank hold BNGO as of Q1 2022.

  • AQR Capital Management reported no remaining Bionano Genomics position as of Q1 2022 after selling out during the quarter.
  • AQR Capital Management sold 196 Bionano Genomics shares in Q1 2022, an estimated $352K.
  • AQR Capital Management first reported a position in Bionano Genomics in Q2 2021 and held it in 3 quarters.
  • AQR Capital Management's Bionano Genomics position peaked at $541K in Q3 2021.
  • 148 funds tracked by Wall St. Rank held Bionano Genomics as of Q1 2022.

Based on AQR Capital Management's 13F filing for Q1 2022, filed 16 May 2022.